The Pharma Data

NOVEMBER 15, 2020

” Arthur Oubrie, Chief Scientific Officer of Lead Pharma, added: “This is the second project we partner with one of the largest pharmaceutical companies under our Discover, Design and Deliver platform. . OSS, Netherlands , Nov. About Lead Pharma. For more information visit: www.leadpharma.com.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

DECEMBER 27, 2020

United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership.

FDA 52

FDA Bioinformatics Disease Production 52

The Pharma Data

OCTOBER 27, 2020

Impairment of investment in privately-held company (2). Unrealized gain on investment in privately-held company (3). License-related fees (5). License-related fees (5). 2020.

FDA 40

FDA Production Licensing Licensing 40

Drug Target Review

FEBRUARY 11, 2025

The major hurdles that pharmaceutical companies face are long lead times, high costs and a low probability of success (PoS). Managing this data deluge requires the expertise of multidisciplinary fields like clinical bioinformatics , which bridges statistics, biology and computer science.

Drug Development 59

Drug Development Bioinformatics Small Molecule Drugs 59